Guidelines for the hormone treatment of women in the menopausal transition and beyond: Position Statement by the Executive Committee of the International Menopause Society

Maturitas

Volume 48, Issue 1, 28 May 2004, Pages 27-31

Click to open first page preview

O Joakimsen et al.
Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis
J. Clin. Epidemiol.
(2000)
W.J Mack et al.
Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the estrogen in the prevention of atherosclerosis trial
Atherosclerosis
(2003)
J.E Rossouw et al.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial
J. Am. Med. Assoc.
(2002)
J.E Manson et al.
Estrogen plus progestin and the risk of coronary heart disease
N. Engl. J. Med.
(2003)
R.T Chlebowski et al.
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women’s Health Initiative Randomized Trial
J. Am. Med. Assoc.
(2003)
Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet...
S Hulley et al.
Randomized trial of estrogen plus progestin for secondary prevention of coronary disease in postmenopausal women
J. Am. Med. Assoc.
(1998)
D.M Herrington et al.
Effects of estrogen replacement on the progression of coronary artery atherosclerosis
N. Engl. J. Med.
(2000)

There are more references available in the full text version of this article.

^☆: This IMS Position Statement was first published in Climacteric 2004;7:8–11. This statement is reproduced in Maturitas with permission from The International Menopause Society.